SingleCognitive & Sleep

Selank 10mg

Synthetic tuftsin-derived heptapeptide studied for anxiolytic, nootropic, and neurochemical modulatory properties in research settings.

Mechanism

Selank influences central nervous system function by modulating GABA-A receptor gene expression independently of the benzodiazepine binding site, inhibiting enkephalin-degrading enzymes, and upregulating brain-derived neurotrophic factor (BDNF).

Dosing

Standard laboratory protocols document an initial daily research dose of 300 mcg administered subcutaneously.

Reconstitution

Diluting a 10 mg vial with 3.0 mL of bacteriostatic water results in a final working concentration of approximately 3.33 mg/mL (3,333 mcg/mL).

Storage

Preserve unmixed lyophilized vials at -20 °C protected from illumination, and maintain reconstituted solutions at 2–8 °C without freezing for up to 28 days.

Mix & measure Selank 10mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Selank 10mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration3.33mg/mL

Draw volume0.090mL

On the syringe9.00units

Total doses in vial: 33.3

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	300 mcg (1× daily)	~9 units (0.09 mL)
Weeks 3–4	500 mcg (1× daily)	~15 units (0.15 mL)

Reconstitution Steps

1
Draw exactly 3.0 mL of bacteriostatic water into a sterile mixing syringe.
2
Introduce the diluent slowly against the inside glass wall of the Selank vial to avoid agitation and foaming.
3
Swirl or roll the vial gently between the palms until the lyophilized cake is fully dissolved; avoid vigorous shaking.
4
Mark the vial with the preparation date and resulting concentration, then store immediately at 2–8 °C shielded from light.

Supplies Needed

Peptide Vial

Provides 10 mg of lyophilized Selank for experimental evaluation

Insulin Syringes (U-100)

Facilitates precise measurement and administration of micro-volume research doses

Bacteriostatic Water

Acts as the sterile, preserved diluent to reconstitute the peptide cake

Alcohol Swabs

Maintains aseptic technique when sanitizing the vial septum and injection surfaces

Why researchers study it

Investigation of non-sedating anxiolytic mechanisms

Evaluation of cognitive enhancement and mental fatigue reduction

Exploration of tuftsin-related immunomodulatory pathways

Assessment of BDNF, GABA-A, and monoamine neurotransmission changes

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Selank is a synthetic heptapeptide engineered as an analog of the naturally occurring immunomodulatory peptide tuftsin. Designed initially in Russia to improve molecular stability, it has garnered significant attention in experimental neuroscience for its dual potential as a non-sedating anxiolytic and cognitive enhancer. The peptide features the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, which grants it enhanced resistance to enzymatic degradation relative to native tuftsin. In preclinical and clinical research, Selank is investigated primarily for its capacity to blunt anxiety and reduce mental fatigue without producing the classical sedative, myorelaxant, or habit-forming effects associated with conventional benzodiazepines. In addition to behavioral outcomes, laboratory work has uncovered immunomodulatory characteristics and positive influences on central neurotrophic factors. Although licensed as a prescription nasal spray in select Eastern European countries, Selank remains an unapproved investigational compound in the United States and European Union. Contemporary scientific investigation focuses on delineating its receptor-level mechanisms, neurochemical pathways, and comparative bioactivity across different experimental delivery methods.

References

1.Zozulya et al., PubMed, 2008 — randomized human trial examining efficacy and safety of intranasal Selank in generalized anxiety disorder
2.Medvedev et al., PubMed, 2014 — 14-day intranasal study assessing anxiolytic and anti-asthenic effects of Selank in neurasthenia
3.Hindawi / BioMed Research International, Review, 2008 — pharmacology, neurobehavioral effects, and clinical applications of intranasal Selank
4.DrugBank / Pharmacology, Database Entry, 2020 — rapid plasma degradation and pharmacokinetic profile of Selank
5.Animal Studies, PubMed, 2010 — preclinical research regarding Selank effects on monoamine metabolism and BDNF expression